Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data
Katherine A Kelly,1 Patrick O Perche,1 Steven R Feldman1– 4 1Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 2Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 3Department of Social Sciences & Heal...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-06-01
|
| Series: | Clinical, Cosmetic and Investigational Dermatology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/therapeutic-potential-of-tralokinumab-in-the-treatment-of-atopic-derma-peer-reviewed-fulltext-article-CCID |
| _version_ | 1811246255327674368 |
|---|---|
| author | Kelly KA Perche PO Feldman SR |
| author_facet | Kelly KA Perche PO Feldman SR |
| author_sort | Kelly KA |
| collection | DOAJ |
| description | Katherine A Kelly,1 Patrick O Perche,1 Steven R Feldman1– 4 1Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 2Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 3Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA; 4Department of Dermatology, University of Southern Denmark, Odense, DenmarkCorrespondence: Steven R Feldman, Department of Dermatology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157-1071, USA, Tel +1 336-716-7740, Fax +1 336-716-7732, Email sfeldman@wakehealth.eduAbstract: Atopic dermatitis (AD) is a chronic inflammatory skin disease that greatly impacts patient quality of life. Type 2 cytokine interleukin (IL)-13 is integral to the pathogenesis of AD. Tralokinumab is a fully human IgG4 monoclonal antibody that specifically targets IL-13, preventing downstream signaling of inflammatory pathways that may contribute to AD. Tralokinumab was US Food and Drug administration (FDA) recently approved for the treatment of moderate to severe AD on December 28, 2021. In our review, we will explore the efficacy and adverse effects (AEs) of tralokinumab for the treatment of patients with moderate to severe AD. A PubMed search for key articles on the emerging clinical data of tralokinumab was performed. Six randomized controlled trials of tralokinumab identified improvements in disease severity measures, including Investigator’s Global Assessment (IGA) scores and Eczema Area Severity Index 75 (EASI75) scores. Four of these studies demonstrated improvements in quality of life measures with tralokinumab, including pruritus scores, sleep interference scores, Dermatology Life Quality Index, SCORing Atopic Dermatitis (SCORAD), Patient Oriented Eczema Measure, and The Short Form 36 Health Survey (SF-36v2) scores. One study identified a similar immune response in patients taking tralokinumab to those taking the Tdap and meningococcal vaccines. Upper respiratory infection, conjunctivitis, and headaches were the most common adverse events. The varying criteria to assess changes in AD disease severity across different studies is a limitation of this review. Tralokinumab is another promising biologic option for the treatment of moderate to severe AD, which may reduce disease burden and improve patient quality of life.Keywords: biosimilar, biologic, non-medical switching, real-world data |
| first_indexed | 2024-04-12T14:50:54Z |
| format | Article |
| id | doaj.art-9fefed5a007442018a3a2089d20f5e82 |
| institution | Directory Open Access Journal |
| issn | 1178-7015 |
| language | English |
| last_indexed | 2024-04-12T14:50:54Z |
| publishDate | 2022-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical, Cosmetic and Investigational Dermatology |
| spelling | doaj.art-9fefed5a007442018a3a2089d20f5e822022-12-22T03:28:27ZengDove Medical PressClinical, Cosmetic and Investigational Dermatology1178-70152022-06-01Volume 151037104375707Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical DataKelly KAPerche POFeldman SRKatherine A Kelly,1 Patrick O Perche,1 Steven R Feldman1– 4 1Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 2Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 3Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA; 4Department of Dermatology, University of Southern Denmark, Odense, DenmarkCorrespondence: Steven R Feldman, Department of Dermatology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157-1071, USA, Tel +1 336-716-7740, Fax +1 336-716-7732, Email sfeldman@wakehealth.eduAbstract: Atopic dermatitis (AD) is a chronic inflammatory skin disease that greatly impacts patient quality of life. Type 2 cytokine interleukin (IL)-13 is integral to the pathogenesis of AD. Tralokinumab is a fully human IgG4 monoclonal antibody that specifically targets IL-13, preventing downstream signaling of inflammatory pathways that may contribute to AD. Tralokinumab was US Food and Drug administration (FDA) recently approved for the treatment of moderate to severe AD on December 28, 2021. In our review, we will explore the efficacy and adverse effects (AEs) of tralokinumab for the treatment of patients with moderate to severe AD. A PubMed search for key articles on the emerging clinical data of tralokinumab was performed. Six randomized controlled trials of tralokinumab identified improvements in disease severity measures, including Investigator’s Global Assessment (IGA) scores and Eczema Area Severity Index 75 (EASI75) scores. Four of these studies demonstrated improvements in quality of life measures with tralokinumab, including pruritus scores, sleep interference scores, Dermatology Life Quality Index, SCORing Atopic Dermatitis (SCORAD), Patient Oriented Eczema Measure, and The Short Form 36 Health Survey (SF-36v2) scores. One study identified a similar immune response in patients taking tralokinumab to those taking the Tdap and meningococcal vaccines. Upper respiratory infection, conjunctivitis, and headaches were the most common adverse events. The varying criteria to assess changes in AD disease severity across different studies is a limitation of this review. Tralokinumab is another promising biologic option for the treatment of moderate to severe AD, which may reduce disease burden and improve patient quality of life.Keywords: biosimilar, biologic, non-medical switching, real-world datahttps://www.dovepress.com/therapeutic-potential-of-tralokinumab-in-the-treatment-of-atopic-derma-peer-reviewed-fulltext-article-CCIDbiosimilarbiologicnon-medical switchingreal-world data |
| spellingShingle | Kelly KA Perche PO Feldman SR Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data Clinical, Cosmetic and Investigational Dermatology biosimilar biologic non-medical switching real-world data |
| title | Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data |
| title_full | Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data |
| title_fullStr | Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data |
| title_full_unstemmed | Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data |
| title_short | Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data |
| title_sort | therapeutic potential of tralokinumab in the treatment of atopic dermatitis a review on the emerging clinical data |
| topic | biosimilar biologic non-medical switching real-world data |
| url | https://www.dovepress.com/therapeutic-potential-of-tralokinumab-in-the-treatment-of-atopic-derma-peer-reviewed-fulltext-article-CCID |
| work_keys_str_mv | AT kellyka therapeuticpotentialoftralokinumabinthetreatmentofatopicdermatitisareviewontheemergingclinicaldata AT perchepo therapeuticpotentialoftralokinumabinthetreatmentofatopicdermatitisareviewontheemergingclinicaldata AT feldmansr therapeuticpotentialoftralokinumabinthetreatmentofatopicdermatitisareviewontheemergingclinicaldata |